Compare RNW & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | EVO |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United Kingdom | Germany |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 778.3M |
| IPO Year | 2021 | 2007 |
| Metric | RNW | EVO |
|---|---|---|
| Price | $6.84 | $1.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | $7.00 |
| AVG Volume (30 Days) | ★ 2.9M | 41.1K |
| Earning Date | 06-15-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $11.50 | $10.05 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $1.80 |
| 52 Week High | $8.24 | $4.27 |
| Indicator | RNW | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 63.44 | 34.99 |
| Support Level | $6.78 | N/A |
| Resistance Level | $6.85 | $1.97 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 50.00 | 13.68 |
ReNew Energy Global PLC is a developer and operator of clean energy projects. Additionally, it provides clean energy solutions and value-added energy offerings through digitalization, storage, and carbon market services that are increasingly integral to addressing climate change. The company has two reportable segments: Generation and sale of renewable power and Manufacturing of power equipment. The majority of its revenue is generated from the Generation and sale of renewable power segment, which reflects the revenue earned from its utility-scale wind energy projects, solar energy projects, and hydro energy projects. The Manufacturing of power equipment segment relates to the manufacturing of solar panels and modules. Geographically, all of its material revenues are generated from India.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.